IDEXX Total Current Liabilities vs Cash Analysis

IDXX Stock

USD 437.30 4.02 0.93%

IDEXX Laboratories financial indicator trend analysis is infinitely more than just investigating IDEXX Laboratories recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether IDEXX Laboratories is a good investment. Please check the relationship between IDEXX Laboratories Total Current Liabilities and its Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

Total Current Liabilities vs Cash

Total Current Liabilities vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of IDEXX Laboratories Total Current Liabilities account and Cash. At this time, the significance of the direction appears to have very week relationship.

The correlation between IDEXX Laboratories' Total Current Liabilities and Cash is 0.27. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Cash in the same time period over historical financial statements of IDEXX Laboratories, assuming nothing else is changed. The correlation between historical values of IDEXX Laboratories' Total Current Liabilities and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of IDEXX Laboratories are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Current Liabilities i.e., IDEXX Laboratories' Total Current Liabilities and Cash go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on IDEXX Laboratories balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of IDEXX Laboratories are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash

Cash refers to the most liquid asset of IDEXX Laboratories, which is listed under current asset account on IDEXX Laboratories balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from IDEXX Laboratories customers. The amounts must be unrestricted with restricted cash listed in a different IDEXX Laboratories account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from IDEXX Laboratories' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 44.60 in 2024, whereas Selling General Administrative is likely to drop slightly above 171.1 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	1.9B	2.0B	2.2B	2.3B
Total Revenue	3.2B	3.4B	3.7B	3.8B

Gross Profit Total Revenue

IDEXX Laboratories fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Short Term Debt	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock
Total Assets		0.97	0.75	0.73	0.98	0.33	0.91	0.95	0.63	0.98	0.84	0.48	0.99	-0.32	0.97	0.97	-0.92	0.82	0.96	0.77	0.72	0.63	0.11	0.9	0.6	0.54
Other Current Liab	0.97		0.7	0.65	0.99	0.39	0.86	0.97	0.52	0.98	0.88	0.36	0.98	-0.42	0.92	0.95	-0.89	0.85	0.89	0.86	0.7	0.65	0.04	0.88	0.58	0.54
Total Current Liabilities	0.75	0.7		0.19	0.75	0.77	0.52	0.77	0.27	0.69	0.46	0.48	0.72	-0.28	0.76	0.8	-0.65	0.92	0.78	0.73	0.57	0.93	0.73	0.49	0.67	0.67
Total Stockholder Equity	0.73	0.65	0.19		0.64	-0.39	0.89	0.59	0.75	0.72	0.73	0.33	0.71	0.05	0.74	0.65	-0.75	0.2	0.69	0.19	0.61	-0.06	-0.39	0.82	0.25	0.14
Property Plant And Equipment Net	0.98	0.99	0.75	0.64		0.42	0.86	0.96	0.52	0.99	0.85	0.36	0.99	-0.39	0.94	0.96	-0.9	0.86	0.9	0.85	0.69	0.68	0.1	0.86	0.62	0.58
Net Debt	0.33	0.39	0.77	-0.39	0.42		0.0	0.47	-0.29	0.32	0.15	0.1	0.35	-0.52	0.31	0.41	-0.22	0.79	0.31	0.72	0.2	0.91	0.74	0.07	0.47	0.51
Retained Earnings	0.91	0.86	0.52	0.89	0.86	0.0		0.84	0.67	0.92	0.85	0.3	0.9	-0.19	0.93	0.9	-0.97	0.55	0.83	0.5	0.76	0.31	-0.11	0.89	0.41	0.33
Accounts Payable	0.95	0.97	0.77	0.59	0.96	0.47	0.84		0.4	0.97	0.85	0.3	0.97	-0.43	0.93	0.95	-0.89	0.86	0.87	0.83	0.74	0.69	0.15	0.87	0.58	0.53
Cash	0.63	0.52	0.27	0.75	0.52	-0.29	0.67	0.4		0.52	0.39	0.76	0.55	0.18	0.56	0.52	-0.55	0.27	0.73	0.23	0.36	0.11	-0.14	0.61	0.4	0.32
Non Current Assets Total	0.98	0.98	0.69	0.72	0.99	0.32	0.92	0.97	0.52		0.9	0.31	0.99	-0.37	0.96	0.97	-0.94	0.79	0.89	0.78	0.74	0.59	0.03	0.9	0.55	0.5
Non Currrent Assets Other	0.84	0.88	0.46	0.73	0.85	0.15	0.85	0.85	0.39	0.9		0.09	0.88	-0.32	0.83	0.82	-0.83	0.59	0.7	0.62	0.68	0.35	-0.19	0.82	0.38	0.33
Cash And Short Term Investments	0.48	0.36	0.48	0.33	0.36	0.1	0.3	0.3	0.76	0.31	0.09		0.39	0.08	0.39	0.34	-0.23	0.41	0.7	0.31	0.12	0.42	0.3	0.38	0.43	0.39
Net Receivables	0.99	0.98	0.72	0.71	0.99	0.35	0.9	0.97	0.55	0.99	0.88	0.39		-0.38	0.96	0.96	-0.91	0.82	0.92	0.8	0.7	0.62	0.06	0.9	0.57	0.51
Common Stock Shares Outstanding	-0.32	-0.42	-0.28	0.05	-0.39	-0.52	-0.19	-0.43	0.18	-0.37	-0.32	0.08	-0.38		-0.27	-0.32	0.3	-0.5	-0.22	-0.63	0.11	-0.48	-0.02	-0.34	0.13	0.2
Inventory	0.97	0.92	0.76	0.74	0.94	0.31	0.93	0.93	0.56	0.96	0.83	0.39	0.96	-0.27		0.97	-0.93	0.77	0.92	0.68	0.78	0.59	0.17	0.87	0.57	0.5
Other Current Assets	0.97	0.95	0.8	0.65	0.96	0.41	0.9	0.95	0.52	0.97	0.82	0.34	0.96	-0.32	0.97		-0.96	0.83	0.9	0.76	0.8	0.67	0.21	0.83	0.6	0.55
Other Stockholder Equity	-0.92	-0.89	-0.65	-0.75	-0.9	-0.22	-0.97	-0.89	-0.55	-0.94	-0.83	-0.23	-0.91	0.3	-0.93	-0.96		-0.68	-0.82	-0.62	-0.79	-0.48	-0.06	-0.84	-0.49	-0.42
Total Liab	0.82	0.85	0.92	0.2	0.86	0.79	0.55	0.86	0.27	0.79	0.59	0.41	0.82	-0.5	0.77	0.83	-0.68		0.8	0.94	0.51	0.95	0.49	0.6	0.65	0.65
Total Current Assets	0.96	0.89	0.78	0.69	0.9	0.31	0.83	0.87	0.73	0.89	0.7	0.7	0.92	-0.22	0.92	0.9	-0.82	0.8		0.71	0.64	0.66	0.22	0.84	0.62	0.56
Non Current Liabilities Total	0.77	0.86	0.73	0.19	0.85	0.72	0.5	0.83	0.23	0.78	0.62	0.31	0.8	-0.63	0.68	0.76	-0.62	0.94	0.71		0.4	0.85	0.23	0.61	0.55	0.55
Intangible Assets	0.72	0.7	0.57	0.61	0.69	0.2	0.76	0.74	0.36	0.74	0.68	0.12	0.7	0.11	0.78	0.8	-0.79	0.51	0.64	0.4		0.35	0.15	0.64	0.65	0.63
Short Long Term Debt Total	0.63	0.65	0.93	-0.06	0.68	0.91	0.31	0.69	0.11	0.59	0.35	0.42	0.62	-0.48	0.59	0.67	-0.48	0.95	0.66	0.85	0.35		0.69	0.37	0.59	0.62
Short Term Debt	0.11	0.04	0.73	-0.39	0.1	0.74	-0.11	0.15	-0.14	0.03	-0.19	0.3	0.06	-0.02	0.17	0.21	-0.06	0.49	0.22	0.23	0.15	0.69		-0.18	0.43	0.47
Property Plant And Equipment Gross	0.9	0.88	0.49	0.82	0.86	0.07	0.89	0.87	0.61	0.9	0.82	0.38	0.9	-0.34	0.87	0.83	-0.84	0.6	0.84	0.61	0.64	0.37	-0.18		0.38	0.28
Common Stock Total Equity	0.6	0.58	0.67	0.25	0.62	0.47	0.41	0.58	0.4	0.55	0.38	0.43	0.57	0.13	0.57	0.6	-0.49	0.65	0.62	0.55	0.65	0.59	0.43	0.38		0.97
Common Stock	0.54	0.54	0.67	0.14	0.58	0.51	0.33	0.53	0.32	0.5	0.33	0.39	0.51	0.2	0.5	0.55	-0.42	0.65	0.56	0.55	0.63	0.62	0.47	0.28	0.97

Click cells to compare fundamentals

IDEXX Laboratories Account Relationship Matchups

IDEXX Laboratories fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Other Current Liab	322.9M	415.6M	458.9M	433.7M	478.7M	502.6M
Total Current Liabilities	725.3M	582.8M	763.6M	1.2B	951.5M	999.1M
Total Stockholder Equity	177.5M	632.1M	690.0M	608.7M	1.5B	1.6B
Property Plant And Equipment Net	533.8M	555.2M	587.7M	649.5M	702.2M	737.3M
Net Debt	897.3M	524.6M	779.2M	1.2B	493.9M	255.9M
Retained Earnings	1.6B	2.2B	2.9B	3.6B	4.4B	4.7B
Accounts Payable	72.2M	74.6M	116.1M	110.2M	110.6M	116.2M
Cash	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Non Current Assets Total	1.2B	1.2B	1.5B	1.6B	1.8B	1.9B
Non Currrent Assets Other	299.0M	337.2M	397.4M	425.6M	448.5M	470.9M
Cash And Short Term Investments	90.3M	383.9M	144.5M	112.5M	453.9M	476.6M
Net Receivables	269.3M	331.4M	368.3M	400.6M	457.4M	480.3M
Common Stock Shares Outstanding	87.5M	86.7M	86.6M	84.6M	84.0M	94.9M
Liabilities And Stockholders Equity	1.8B	2.3B	2.4B	2.7B	3.3B	3.4B
Inventory	195.0M	209.9M	269.0M	367.8M	380.3M	399.3M
Other Current Assets	125.0M	137.5M	173.8M	220.5M	203.6M	213.8M
Other Stockholder Equity	(1.4B)	(1.5B)	(2.2B)	(2.9B)	(2.9B)	(2.8B)
Total Liab	1.7B	1.7B	1.7B	2.1B	1.8B	1.9B
Total Current Assets	679.6M	1.1B	955.7M	1.1B	1.5B	1.6B
Non Current Liabilities Total	929.3M	1.1B	983.6M	902.2M	823.8M	865.0M
Intangible Assets	58.5M	52.5M	99.0M	97.7M	84.5M	74.5M
Short Long Term Debt Total	987.7M	908.5M	923.7M	1.3B	947.9M	995.3M
Short Term Debt	288.8M	50.0M	148.5M	654.0M	325.0M	208.6M
Property Plant And Equipment Gross	614.5M	646.3M	1.3B	649.5M	1.6B	1.7B
Accumulated Other Comprehensive Income	(46.2M)	(53.6M)	(53.5M)	(77.8M)	(71.2M)	(67.6M)
Common Stock Total Equity	10.6M	10.6M	10.7M	10.7M	12.3M	9.0M
Common Stock	10.6M	10.6M	10.7M	10.7M	10.8M	9.2M
Other Assets	240.2M	676.7M	893.9M	387.5M	445.6M	467.9M
Treasury Stock	(2.3B)	(2.6B)	(2.8B)	(3.6B)	(3.2B)	(3.1B)
Property Plant Equipment	533.8M	555.2M	587.7M	649.5M	746.9M	784.2M
Current Deferred Revenue	41.5M	42.6M	40.0M	37.9M	37.2M	25.0M
Good Will	239.7M	243.3M	359.3M	361.8M	366.0M	206.0M
Other Liab	162.8M	220.5M	208.4M	106.6M	122.6M	83.3M
Long Term Debt	698.9M	858.5M	775.2M	694.4M	622.9M	380.8M
Net Tangible Assets	(120.7M)	336.2M	690.0M	149.3M	134.3M	141.1M
Noncontrolling Interest In Consolidated Entity	264K	280K	352K	707K	813.1K	853.7K
Retained Earnings Total Equity	1.6B	2.2B	2.9B	3.6B	4.1B	4.3B
Long Term Debt Total	698.9M	858.5M	775.2M	694.4M	798.5M	502.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

IDEXX Total Current Liabilities vs Cash Analysis

Total Current Liabilities vs Cash

Total Current Liabilities vs Cash Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Cash

IDEXX Laboratories fundamental ratios Correlations

IDEXX Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

IDEXX Laboratories fundamental ratios Accounts

Also Currently Popular

Additional Tools for IDEXX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Other Current Liab
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Net Receivables	+ 0.99	Property Plant And Equipment Net
Net Receivables	+ 0.99	Non Current Assets Total
Property Plant And Equipment Net	+ 0.98	Total Assets

Other Stockholder Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Other Current Assets
Other Stockholder Equity	- 0.94	Non Current Assets Total
Other Stockholder Equity	- 0.93	Inventory
Other Stockholder Equity	- 0.92	Total Assets
Other Stockholder Equity	- 0.91	Net Receivables